Big pharma is coughing up some pocket change for Botox. Actavis announced it will buy Botox manufacturer Allergan for $66 billion. The acquisition means Actavis is expected to generate $23 billion annually, according to its president, and will become one of the top 10 biggest pharmaceutical companies. The deal was approved the two boards, but will need shareholder approval. It's expected to finalize next year.
